Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03711578
Title Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rhizen Pharmaceuticals SA
Indications

lymphoplasmacytic lymphoma

marginal zone B-cell lymphoma

chronic lymphocytic leukemia/small lymphocytic lymphoma

Waldenstroem's macroglobulinemia

follicular lymphoma

Therapies

Tenalisib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.